Schering-Plough Merger Offers Merck OTC Business, Zegerid Switch Rights
This article was originally published in The Pink Sheet Daily
Executive Summary
No one product, Merck CEO Clark says, will account for more than 10 percent of the combined company’s sales, which will be nearly $47 billion based on 2008 figures.